临床合理用药杂志
臨床閤理用藥雜誌
림상합리용약잡지
CHINESE JOURNAL OF CLINICAL RATIONAL DRUG USE
2014年
12期
7-8
,共2页
肝炎,乙型,慢性%肝炎表面抗原,乙型%阿德福韦酯%替比夫定
肝炎,乙型,慢性%肝炎錶麵抗原,乙型%阿德福韋酯%替比伕定
간염,을형,만성%간염표면항원,을형%아덕복위지%체비부정
Hepatitis B,chronic%Hepatitis B surface,antigens%Adefovir dipivoxil%Telbivudine
目的：探讨替比夫定联合阿德福韦酯治疗慢性乙型肝炎的疗效。方法选择2O1O 年3月-2O12年3月于本院就诊的 HBsAg 阳性慢性乙型肝炎患者75例，将其随机分为两组。对照组35例患者采用替比夫定1OOmg/ d 治疗，研究组4O 例患者采用替比夫定联合阿德福韦酯治疗。分别观察治疗12、24、36、48周后 HBsAg 转阴率和肝功能等各项指标。结果两组患者治疗后12、24周，HBV - DNA 与 HBsAg 转阴例数比较，差异无统计学意义（ P >O. O5），治疗后36、48周两组比较差异有统计学意义（P < O. O5）。两组患者治疗前 AST、ALT、总胆红素（TBIL）、HBV - DNA 比差异无统计学意义（P > O. O5），治疗后研究组小于对照组，差异有统计学意义（P < O. O5）。结论替比夫定与阿德福韦酯联合使用治疗慢性乙型肝炎疗效优于单用替比夫定，适宜临床推广。
目的：探討替比伕定聯閤阿德福韋酯治療慢性乙型肝炎的療效。方法選擇2O1O 年3月-2O12年3月于本院就診的 HBsAg 暘性慢性乙型肝炎患者75例，將其隨機分為兩組。對照組35例患者採用替比伕定1OOmg/ d 治療，研究組4O 例患者採用替比伕定聯閤阿德福韋酯治療。分彆觀察治療12、24、36、48週後 HBsAg 轉陰率和肝功能等各項指標。結果兩組患者治療後12、24週，HBV - DNA 與 HBsAg 轉陰例數比較，差異無統計學意義（ P >O. O5），治療後36、48週兩組比較差異有統計學意義（P < O. O5）。兩組患者治療前 AST、ALT、總膽紅素（TBIL）、HBV - DNA 比差異無統計學意義（P > O. O5），治療後研究組小于對照組，差異有統計學意義（P < O. O5）。結論替比伕定與阿德福韋酯聯閤使用治療慢性乙型肝炎療效優于單用替比伕定，適宜臨床推廣。
목적：탐토체비부정연합아덕복위지치료만성을형간염적료효。방법선택2O1O 년3월-2O12년3월우본원취진적 HBsAg 양성만성을형간염환자75례，장기수궤분위량조。대조조35례환자채용체비부정1OOmg/ d 치료，연구조4O 례환자채용체비부정연합아덕복위지치료。분별관찰치료12、24、36、48주후 HBsAg 전음솔화간공능등각항지표。결과량조환자치료후12、24주，HBV - DNA 여 HBsAg 전음례수비교，차이무통계학의의（ P >O. O5），치료후36、48주량조비교차이유통계학의의（P < O. O5）。량조환자치료전 AST、ALT、총담홍소（TBIL）、HBV - DNA 비차이무통계학의의（P > O. O5），치료후연구조소우대조조，차이유통계학의의（P < O. O5）。결론체비부정여아덕복위지연합사용치료만성을형간염료효우우단용체비부정，괄의림상추엄。
Objective To study the clinical effect of telbivudine combined with adefovir dipivoxil treating chronic hepatitis B. Methods 75 patients of HBsAg positive chronic hepatitis B from Mar. 2O11 to Mar. 2O12 were divided into study group and controll group. The study group was treated with telbivudine combined with adefovir dipivoxil,the controll group was treated with telbivudine only. The negative conversion ratio of HBsAg and liver function of two groups were compared at 12 weeks,24 weeks,36 weeks and 48 weeks after treatment. Results Negative conversion of the two groups were compared at 12,24 weeks after treatment,the difference was not statistically significant(P > O. O5),but 36,48 weeks which were com-pared,the difference was statistically significant(P < O. O5). The results of AST,ALT,total bilirubin(TBIL)and HBV -DNA before treatment of the two groups were compared,the differences were not statistically significant(P > O. O5);The re-sults of AST,ALT,TBIL and HBV - DNA of study group were better than controlled group after treatment,the difference was statistically significant(P < O. O5). Conclusion Treating HBsAg positive chronic hepatitis B with telbivudine combine with adefovir dipivoxil can receive better effect than using telbivudine only,it is suitable for clinical promotion.
